Cargando…
In Vivo Anticancer Activity of AZD3965: A Systematic Review
Proliferating cancer cells have high energy demands, which is mainly obtained through glycolysis. The transmembrane trafficking of lactate, a major metabolite produced by glycolytic cancer cells, relies on monocarboxylate transporters (MCTs). MCT1 optimally imports lactate, although it can work bidi...
Autores principales: | Silva, Ana, Antunes, Beatriz, Batista, Alberta, Pinto-Ribeiro, Filipa, Baltazar, Fátima, Afonso, Julieta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746498/ https://www.ncbi.nlm.nih.gov/pubmed/35011413 http://dx.doi.org/10.3390/molecules27010181 |
Ejemplares similares
-
Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
por: Braga, Marta, et al.
Publicado: (2020) -
In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
por: Benyahia, Zohra, et al.
Publicado: (2021) -
Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
por: Beloueche-Babari, Mounia, et al.
Publicado: (2020) -
Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review
por: Silva, Ana, et al.
Publicado: (2023) -
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
por: McNeillis, Rosie, et al.
Publicado: (2020)